Qualigen Therapeutics (QLGN) announced that it received an expected deficiency notification letter from Nasdaq on April 24. The notice indicated that the company was not in compliance with Nasdaq Listing Rule 5250 as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN: